Key result
Bisoprolol effectively treats hypertension but shows no clinical advantage over other beta-blockers for formulary preference.
Why the study?
The clinical pharmacology and comparative efficacy of bisoprolol for hypertension and angina require review to assess its potential clinical usefulness and formulary inclusion.
Does bisoprolol effectively reduce blood pressure and manage angina compared to other antihypertensive and antianginal agents in patients with hypertension or myocardial ischemia?
Population
Patients with hypertension or myocardial ischemia/angina pectoris
Comparison
Bisoprolol monotherapy or combined with hydrochlorothiazide versus placebo, atenolol, nitrendipine, nifedipine, or verapamil
Design
Review of randomized, blind, placebo-controlled and comparative clinical trials
Authors
Loading...
May inform formulary decisions for bisoprolol and torsemide; leaves open need for head-to-head trials versus contemporary agents.
Does bisoprolol effectively reduce blood pressure and manage angina compared to other antihypertensive and antianginal agents in patients with hypertension or myocardial ischemia?
Bisoprolol is an effective beta-blocker for hypertension and angina, but lacks distinguishing clinical evidence to recommend it over existing beta-blockers for institutional formularies.
Johns et al. (1995) conducted a review in Hypertension or Angina. Bisoprolol vs. Other beta-blockers was evaluated. Bisoprolol is safe and effective for short-term management of hypertension, but lacks clinical evidence distinguishing it from other beta-blockers to recommend institutional formulary inclusion.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: